Tibolone 2.5mg Estradiol Equivalency
Tibolone 2.5mg cannot be directly equated to a specific dose of estradiol because tibolone is a synthetic compound with weak estrogenic, progestogenic, and androgenic actions that produces tissue-specific effects through multiple metabolites, rather than functioning as pure estrogen replacement. 1
Why Direct Equivalency Is Not Possible
Tibolone is fundamentally different from estradiol - it is metabolized into three active compounds (3α-hydroxytibolone with estrogenic activity, 3β-hydroxytibolone with progestogenic activity, and Δ4-tibolone with androgenic activity), creating tissue-specific effects that vary by location in the body 2
Metabolite distribution differs by tissue - in serum, the estrogenic 3α-hydroxytibolone predominates, whereas in the myometrium and vagina, the progestagenic/androgenic Δ4-tibolone predominates, meaning tibolone's estrogenic potency varies dramatically depending on the target tissue 2
Tibolone inhibits sulfatase enzyme in breast tissue, which regulates estrogen formation and decreases local estrogen stimulation - a mechanism completely different from exogenous estradiol administration 1
Clinical Efficacy Comparison
Tibolone 2.5mg daily effectively reduces hot flashes and vaginal dryness in postmenopausal women, with a 90% reduction in hot flushes and 51% reduction in vaginal dryness at 24 weeks 3
When compared head-to-head with combined hormone therapy, tibolone was less effective in relieving vasomotor symptoms (OR 4.16,95% CI 1.50 to 11.58), suggesting it has lower estrogenic potency than standard combined HT regimens 4
The 1.25mg dose of tibolone showed similar efficacy to 2.5mg (78% vs 90% reduction in hot flushes), though benefits occurred more gradually with the lower dose 3
Practical Clinical Context
Standard estradiol replacement doses range from transdermal estradiol 14-100 μg/day or oral estradiol 1-2 mg/day, while conjugated equine estrogen 0.625 mg/day was the standard dose in WHI trials 5, 6
Tibolone's clinical effects on vasomotor symptoms appear roughly comparable to lower-dose estrogen therapy, but this is an imprecise comparison given the different mechanisms of action 4, 3
Tibolone 2.5mg does not increase mammographic density unlike combined HT, and causes less breast tenderness, reflecting its unique tissue-specific profile that cannot be replicated by any dose of estradiol alone 1
Critical Safety Distinction
Tibolone carries different risks than estradiol - it was associated with increased breast cancer recurrence in women with prior breast cancer (OR 1.50,95% CI 1.21 to 1.85) and increased stroke risk in older women (OR 2.18,95% CI 1.12 to 4.21), making risk-benefit calculations fundamentally different from estradiol 1, 4
The LIBERATE trial was halted early due to safety concerns in breast cancer survivors, contrasting with estrogen-alone therapy which showed a small reduction in breast cancer risk in women without prior breast cancer 1, 4
Bottom Line for Clinical Practice
If you need to conceptualize tibolone's estrogenic potency for clinical decision-making, tibolone 2.5mg provides roughly equivalent symptom relief to low-to-moderate dose estrogen therapy (perhaps comparable to transdermal estradiol 25-50 μg/day or oral estradiol 0.5-1 mg/day based on vasomotor symptom control), but this is an oversimplification that ignores tibolone's unique progestogenic and androgenic effects. 4, 3 The more important clinical point is that tibolone should be selected based on its distinct tissue-specific profile rather than as a substitute for a particular estradiol dose 1, 2